Drug
Ibalizumab clinical trials
Also written TNX-355.
- studies test it
- 7
- open now
- 0
- in phase 3
- 3
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
TaiMed Biologics Inc. (4) · David Ho (1) · Kaiser Permanente (1) · Tanox (1)
Often tested with
Tested in the same studies.
VRC07-523LS (1) · Antiretroviral Therapy (1)
Studies
Open first, then newest update. How each study uses ibalizumab is read from its arms, and is right about nine times in ten.
Testing it · 7
- 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected AdultsActive, not recruitingPhase 1David HoNCT05890963Written as 10E8.4/iMab
- Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular InjectionCompletedPhase 3TaiMed Biologics Inc.NCT03913195Written as ibalizumab-uiyk
- Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1CompletedPhase 3TaiMed Biologics Inc.NCT02707861Written as ibalizumab
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIVCompletedPhase 3TaiMed Biologics Inc.NCT02475629Written as ibalizumab
- Investigator-Sponsored Protocol - Continued Use of IbalizumabCompletedPhase 2Kaiser PermanenteNCT01056393Written as ibalizumab 800mg Q2Weeks
- Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1CompletedPhase 2TaiMed Biologics Inc.NCT00784147Written as Ibalizumab
- TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1Status unknownPhase 2TanoxNCT00089700Written as TNX-355
Codes
What other systems call ibalizumab · ClinicalTrials.gg INT004608
- MeSH (NLM) C481504ibalizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) LT369U66CEIBALIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2043283One source FDA
- Wikidata Q3791531ibalizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88612IbalizumabOne source FDA
- DrugBank DB12698One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C481504 | ibalizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | LT369U66CE | IBALIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2043283 | — | One source FDA |
| Wikidata | Q3791531 | ibalizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88612 | Ibalizumab | One source FDA |
| DrugBank | DB12698 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.